CLINUVEL PHARMACEUTICALS WKN: A0JEGY ISIN: AU000000CUV3 Kürzel: CUV Forum: Aktien Thema: Hauptdiskussion

@Daniel - ja es nervt und ich glaube genau das ist es was die Leerverkäufer bei geringem Volumen erreichen wollen. Schau nicht jeden Tag auf den Kurs und lass dich erst recht nicht davon verunsichern.

Kaum freut man sich Mal wieder über 16,17 Euro kommt wieder so ein Absturz

Es nervt

Gibt nix das sind die üblichen Short Angriffe und haben nichts mit dem Unternehmen zu tun. Trotzdem ist so etwas unerträglich und wird hoffentlich bald vom Management adressiert.

Ich konnte auf der Investor Relations Seite keine News finden. Kennt einer den Grund für den Absturz?

Was für ein Gemetzel heute in Australien, -14,68%.

Solides Wachstum - 140Mio Cash und in jeder unternehmerischen Sicht bereit weitere Produkte auszurollen ! Großartige Aussichten. - der Kurs ist weiterhin stark von Leerverkäufen manipuliert also lasst euch deshalb nicht verunsichern

https://www.clinuvel.com/wp-content/uploads/2023/02/appendix-4d-half-yearly-report-20230224.pdf

https://www.fool.com.au/2023/02/24/why-clinuvel-cogstate-omni-bridgeway-and-westgold-shares-are-sinking/ Clinuvel Pharmaceuticals Limited (ASX: CUV) The Clinuvel share price is down 3% to $23.33. This is despite the release of the pharmaceutical company’s half-year results, which revealed explosive earnings growth. Clinuvel reported a 19% increase in revenue and a 94% jump in profit after tax. This was driven by growth in prescriptions and expert centres administering the Scenesse therapy.

Global SCENESSE® demand drives increased CLINUVEL revenues, earnings https://www.globenewswire.com/news-release/2023/02/23/2614910/0/en/Global-SCENESSE-demand-drives-increased-CLINUVEL-revenues-earnings.html

https://youtube.com/watch?v=Hz1SyWyJnyI&feature=share

Danke Odi001 für den Beitrag 👍

https://www.theaustralian.com.au/business/companies/clinuvel-shows-promise-in-creating-skin-cancer-shield-as-afamelanotide-study-delivers-positive-results/news-story/18cf65fff440bd35f3679c5fb2382192 Clinuvel shows promise in creating skin cancer shield as afamelanotide study delivers positive results ASX-listed biotech Clinuvel is planning to expand beyond rare diseases to prevent one of the most common cancers, tapping into a multibillion-dollar market. Clinuvel has completed a successful trial on its drug afamelanotide, with the study showing it reduced damage from UV radiation in people with fair skin. UV radiation damage is a leading factor in skin cancer – which costs $US8.1bn ($11.3bn) to treat each year in the US alone – and photoaging, premature skin ageing from prolonged and repeated exposure to solar radiation. The study showed that afamelanotide could significantly reduce artificially provoked sunburn damage after six days, indicating its potential use in preventing skin cancer development. The trial, completed in the UK, comes after Clinuvel successfully completed a phase two study aimed at protecting patients with xeroderma pigmentosum – a rare genetic disorder that put those with the condition at greater risk of developing aggressive skin cancers. Wilsons analyst Melissa Benson said the positive results from the latest trial were “not earth shattering or unexpected” but “continues to speak to the potential for broader applications” of afamelanotide than treating rare disease. “Melanoma represents a common cancer type, with a high mortality rate, despite treatment advances,” Dr Benson said “Novel therapies to reduce melanoma incidence presents a material opportunity, down the line. “(About) 100,000 new melanoma cases are diagnosed in the US each year, with 8000 deaths owing to melanoma. Australia carries one of the highest burdens of melanoma globally.” Local biotech companies are back on the world stage, with the biggest Australian delegation since the Covid-19 pandemic descending on JP Morgan’s major health conference in San Francisco last month – setting up for a year of deal making. Clinuvel shares advanced 1.8 per cent to $24.56 in afternoon trade on Thursday, giving the company a market value of $1.2bn. Dr Benson maintained an overweight rating on the company with a $30.67 share price target. She said application of afamelanotide on xeroderma pigmentosum (XP) represented 4 per cent of the valuation. Clinuvel started clinical trials of afamelanotide in XP patients in 2020, aiming to assess whether treatment with the drug could safely reduce the number of photoproducts – breakages in the DNA helix known as CPDs – as well as showing improvement in other markers of skin damage. Clinuvel head of clinical operations Pilar Bilbao said further clinical work is ongoing to assess the properties and influence of afamelanotide on other parts of cellular DNA. “Frequent and intense sunburn is recognised as a primary risk factor for skin cancer, with fair skinned individuals,” Dr Bilbao said. “Showing that we can objectively reduce erythema, sunburn DNA damage, under controlled clinical conditions after a single dose of afamelanotide provides our team with valuable data on how this drug, and other similar molecules, can reduce the burden of UV-induced damage.” In a statement to the ASX, Clinuvel said between five and six million cases of skin cancers are diagnosed in the US every year, with UV exposure and fair skin at increased risk. “An estimated $US8.1bn is spent annually treating skin cancers in the US, suggesting more effective preventative measures are required,” the company said.

🎈

Auch wenn sie nicht müssten

Quaterly cashflow kam heute Nacht